TheEdgeResearch
Home / Stocks / ATNFW

ETHZilla Corporation Warrant (ATNFW)

NASDAQ Healthcare Medical - Pharmaceuticals
$0.43 ▼ -6.52%
Market Cap
$2.6M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.41
52-Wk Range
0.36-0.4433
CEO
Lloyd Blair Jordan
Country
US
Currency
USD

ETHZilla Corporation Warrant operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Palo Alto, DE, US. The stock last traded at $0.43, down 6.52% on the session, giving a market capitalisation of $2.6M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -18427.2%. Its beta of 0.41 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
0.57
EV / EBITDA
0.00
Gross margin
0.0%
Operating margin
-402.4%
Net margin
-18427.2%
Return on equity
—
Debt / equity
0.00
Current ratio
2.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
4
IPO date
2017-06-27
Headquarters
Palo Alto, DE, US
About ETHZilla Corporation Warrant

180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to pioneering novel pharmaceutical treatments that address significant unmet medical needs in areas such as inflammatory conditions, fibrotic disorders, and pain management. This research and development effort is powered by the collective expertise of distinguished therapeutics specialists from Oxford University, the Hebrew University, and Stanford University. The company was co-founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016, and maintains its principal office in Palo Alto, California.

Comparable companies

ETHZilla Corporation Warrant is most often compared with the following Healthcare names:

AWHBPTSEIGRQHINDMDVLNOVNNTBLPLXPPTNSQL
More research on ATNFW
ATNFW technical analysis ATNFW TheEdge Score Compare against peers
Open full interactive analysis & DCF →